Core Outcomes and Common Data Elements in Chronic Subdural Hematoma: A Systematic Review of the Literature Focusing on Reported Outcomes. by Chari, Aswin et al.
Core Outcomes and Common Data Elements
in Chronic Subdural Hematoma:
A Systematic Review of the Literature Focusing
on Reported Outcomes
Aswin Chari,1 Katie C. Hocking,1 Ellie Broughton,1,2 Carole Turner,1,3 Thomas Santarius,1
Peter J. Hutchinson,1,3 and Angelos G. Kolias1,3
Abstract
The plethora of studies in chronic subdural hematoma (CSDH) has not resulted in the development of an evidence-based
treatment strategy, largely due to heterogeneous outcome measures that preclude cross-study comparisons and guideline
development. This study aimed to identify and quantify the heterogeneity of outcome measures reported in the CSDH
literature and to build a case for the development of a consensus-based core outcome set. This systematic review adhered
to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and was registered with
the PROSPERO international prospective register of systematic reviews (CRD42014007266). All full-text English lan-
guage studies with >10 patients (prospective) or >100 patients (retrospective) published after 1990 examining clinical
outcomes in CSDH were eligible for inclusion. One hundred two eligible studies were found. There were 14 (13.7%)
randomized controlled trials, one single arm trial (1.0%), 25 (24.5%) cohort comparison studies, and 62 (60.8%) pro-
spective or retrospective cohort studies. Outcome domains reported by the studies included mortality (63.8% of included
studies), recurrence (94.1%), complications (48.0%), functional outcomes (40.2%), and radiological (38.2%) outcomes.
There was significant heterogeneity in the definitions of the outcome measures, as evidenced by the seven different
definitions of the term ‘‘recurrence,’’ with no definition given in 19 studies. The time-points of assessment for all the
outcome domains varied greatly from inpatient/hospital discharge to 18 months. This study establishes and quantifies the
heterogeneity of outcome measure reporting in CSDH and builds the case for the development of a robust consensus-based
core outcome set for future studies to adhere to as part of the Core Outcomes and Common Data Elements in CSDH
(CODE-CSDH) project.
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Introduction
Chronic subdural hematoma (CSDH) is one of the mostcommon neurosurgical conditions, with an incidence of ap-
proximately 10/100,000/year.1–4 It is predominantly a disease of in-
creasing age and its incidence is expected to rise, primarily due to a
continually aging population and the increasing use of anticoagulant/
antiplatelet medication, both well-recognized risk factors.1–4
Surgical treatment of symptomatic CSDH is associated with
good neurological recovery in the majority of patients, but recurrent
disease still affects 10% to 20% of the population, with a resul-
tant impact on functional outcomes and quality of life.3,5 Recently,
it has been noted that CSDH in the elderly is associated with
significant long-term morbidity and mortality and is an indicator of
systemic dysfunction analogous to hip fractures.6 Therefore, a
multi-disciplinary evidence-based approach needs to be adopted for
the treatment of this common condition.2,3
Despite a plethora of studies investigating the management
of CSDH, there remain a number of unanswered questions
about the choice of surgical technique, adjuvant therapies, and post-
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operative care (Fig. 1).3 Many of the studies published in the lit-
erature are small retrospective case series reporting disparate
baseline data, using variable terminology and definitions of oper-
ative technique, and evaluating heterogeneous outcome measures.
This poses significant barriers to establishing an evidence-based
approach to the management of CSDH, something that has been
acknowledged in all three large meta-analyses that have sought to
elucidate the optimal treatment options for CSDH.2,4,7
To overcome these barriers, clinical trial methodologists have
pioneered the development of core outcome sets, ‘‘an agreed
standardized set of outcomes that should be measured and reported,
as a minimum, in all clinical studies and trials in specific areas of
health or health care.’’8,9 Core outcome sets are currently in use in
rheumatoid arthritis, stroke, and traumatic brain injury, and can
improve the quality of studies and maximize the potential to
combine study outcomes for systematic reviews, meta-analyses,
and guideline development.10–12 Importantly, the patient-centered
methodology used to develop these core outcome sets ensures that
outcomes that are important to patients are measured routinely.
Funding bodies like the National Institute for Health Research in
the UK now recommend the use of core outcome sets, if available,
in grant applications for clinical trials.13
Developing a core outcome set is a two-stage process. The first
step involves reviewing the literature to identify the range of out-
come measures used for the particular condition and quantify the
heterogeneity that exists in the published literature. The second step
involves deriving the core outcome set using a structured consensus
process involving all relevant stakeholders, including clinicians,
academics, allied health care professionals, patients and carers. The
development process for core outcome sets has been facilitated by
organizations such as the Core Outcome Measures in Effectiveness
Trials initiative.9,14
This systematic review represents the first step in the process of
developing a core outcome set for CSDH. It aims to identify the
range of outcome measures used in the CSDH literature and
quantify the heterogeneity, building a case for the development of a
consensus-based core outcome set.
Methods
This systematic review adhered to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) statement
and has been registered with the PROSPERO international pro-
spective register of systematic reviews (CRD42014007266).
The MEDLINE and EMBASE databases were searched for the
terms ‘‘chronic AND subdural’’ on January 10, 2014. Titles and
abstracts were screened for relevance. Full-text articles were
then assessed for eligibility according to the following inclusion
criteria: English language full text; publication date post-1990;
examining clinical outcomes of adult patients with CSDH; and
prospective study with >10 patients or retrospective study with
>100 patients.
The reference lists of eligible studies and relevant review articles
were scanned for further studies not identified by the search strat-
egy. The search strategy is summarized in Figure 2. Full text
manuscripts were requested from corresponding authors of studies
that were not accessible.
Relevant data from included studies was collected indepen-
dently by two authors (AC, KCH) via a piloted data collection
tool. Any discrepancies were settled by consultation between
FIG. 1. Key future research areas surrounding the treatment of CSDH (adapted from Kolias and colleagues).3
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the two authors with reference to the original article. Included
studies were examined for pre-determined primary and secondary
outcomes. All reported outcomes were examined for definitions
and time-points. Data was analyzed using Microsoft Excel
(Microsoft Inc., Redmond, WA).
Results
Study details
A total of 102 studies were eligible for inclusion, comprising
21,598 patients. Thirty-two (31.4%) were prospective studies, 66
(64.8%) were retrospective and four (3.9%) had a combination of
prospective and retrospective data. There were 14 (13.7%) ran-
domized controlled trials, one (1.0%) single arm trial, 25 (24.5%)
cohort comparison studies, and 62 (60.8%) cohort studies. Over
time, the number of CSDH studies seems to be rising, reflecting the
increasing incidence and interest in the condition, but the number of
prospective studies does not seem to increase by the same pro-
portion (Fig. 3). A risk-of-bias tool was not applied to the included
studies as the inherent nature of the present study was to assess risk
of bias based on study design and outcome reporting. The complete
list of included studies is provided online (supplementaryAppendix 1;
see online supplementary material at www.liebertpub.com).
Outcomes domains
A number of different outcome domains were reported by the
102 studies including mortality, recurrence, complications, func-
tional outcomes, and radiological outcomes. Thirty-two (31.4%)
studies had clearly defined primary outcomes; only seven of these
had defined primary and secondary outcomes.
Mortality
Sixty-five studies (63.8%) reported patient mortality, of which
15 (14.7%) did not report a time-point for the mortality figure.
In the studies that reported mortality, there was a wide range of
time-points, from ‘‘post-operative’’ or ‘‘discharge’’ up to 18 months,
with some studies reporting multiple time-points (Fig. 4). Apart
from the immediate post-operative period (reported by 25 studies
[24.5%]), the most popular time-point was at 6 months (reported by
10 studies [9.8%]). One study reported mortality via a Kaplan-Meier
curve, with actual follow-up ranging from 4 months to 14 years.
Recurrence
Recurrence was reported by 96 studies (94.1%), highlighting the
importance of this outcome measure in CSDH. Time-points were
highly varied with 47 (46.1%) reporting no time-point and the rest
ranging between inpatient and 12 months. The most common time-
point was at 3 months (19 studies, 18.6%; Fig. 5). The definitions
of recurrence also were highly variable but generally consisted of a
combination of either radiological recurrence, recurrence of symp-
toms, and/or the need for re-operation (n= 96; Table 1). Two studies
included reoperations on the contralateral (unaffected) side as re-
currences. Interestingly, this heterogeneity persisted in the subgroup
of studies looking specifically for recurrence (n= 22; Table 1) and
the higher quality subgroup of randomized controlled trials (n= 12,
Table 1). The most common definition in all the subgroups was
‘‘symptomatic and radiological recurrence requiring reoperation.’’
Complications
Reporting of complications occurred in 49 (48.0%) studies, al-
though the completeness of reporting was highly variable. Three
(2.9%) did not have any definition for complications, eight (7.8%)
reported only a single complication or complications associated
with the study intervention (e.g., of steroids or of tissue plasmin-
ogen activator, 17 (16.7%) reported only surgical/cranial compli-
cations, one (1.0%) reported only medical complications, and
20 (19.6%) reported a comprehensive list of medical and surgical
FIG. 2. Search strategy.
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FIG. 4. Time-points of studies reporting mortality.
FIG. 3. Stacked area chart illustrating the number of prospective and retrospective studies included, stratified by year of publication.
Note that the literature search was conducted in early 2014, so this may be an underestimate of the true number.
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complications. None of the studies classified the complications
according to severity or an established classification system (e.g.,
the Clavien-Dindo classification).15 The time-points were specified
in only 16 (15.7%) studies and varied between ‘‘post-operative’’
and 18 months.
Functional outcomes
Forty-one (40.2%) studies reported some sort of functional pa-
tient outcome, although five (4.9%) of these were subjective as-
sessments and eight studies (7.8%) reported the Glasgow Coma
Scale as an ‘‘outcome measure.’’ Some of the common functional
assessments included the Glasgow Outcome Scale (GOS; 15
studies, 14.7%), the Markwalder Scale (14 studies, 13.7%), and the
modified Rankin Scale (mRS; five studies, 4.9%), Many of the
studies measured multiple functional outcomes at multiple time-
points, with the most common time-points being at discharge and at
3 and 6 months (Fig. 6).
Approximately one-third of the studies (31, 30.4%) reported
the length of stay; however, the discharge criteria were seldom
described and the discharge destination was only described in
seven studies (6.9%).
Radiological outcomes
Thirty-nine (38.2%) studies examined a radiological outcome
measure, mostly with post-operative CT scanning. Outcome mea-
sures used included thickness of post-operative subdural collection
(11 studies, 10.8%), volume of the post-operative subdural col-
lection (five studies, 4.9%), midline shift (seven studies, 6.9%), the
presence of intra-cranial air (11 studies, 10.8%), assessment
of drain catheter tip position (seven studies, 6.9%) and
FIG. 5. Time-points for reporting of ‘‘recurrence’’ in 96 chronic subdural hematoma studies.
Table 1. Percentage of Studies Providing Various Definitions for the Term ‘‘Recurrence’’
A: All studies
(n = 96)
B: Subgroup of studies looking
at recurrence (n= 22)
C: Subgroup of
RCTs (n= 12)
No definition 19.8% 4.5% 25.0%
Reoperation only 16.7% 9.1% 8.3%
Radiological recurrence 9.4% 18.2% 8.3%
Radiological recurrence, requiring reoperation 2.1% 4.5% 0.0%
Symptomatic or radiological recurrence 6.3% 9.1% 8.3%
Symptomatic or radiological recurrence, requiring reoperation 6.3% 4.5% 0.0%
Symptomatic recurrence, requiring reoperation 2.1% 0.0% 0.0%
Symptomatic and radiological recurrence 8.3% 13.6% 16.7%
Symptomatic and radiological recurrence, requiring reoperation 29.2% 36.4% 33.3%
Subgroup analyses of studies specifically looking at recurrence (n = 22) and RCTs (n= 12) show this heterogeneity persists even in the so-called higher
quality studies.
RCT, randomized controlled trial.
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dichotomous assessments of ‘‘resolved,’’ ‘‘residual/recurrent’’
collections (19 studies, 18.6%). The time-points of these post-
operative scans varied from 3 h post-op up to 6 months. A number
of studies followed strict post-operative protocols for scanning
(e.g., at 1 day, 1 week, 1 month, 3 months, and 6 months post-
operatively) and five studies (4.9%) did not specify when post-
operative scans were performed.
Discussion
This systematic review highlights the heterogeneity of outcome
measures used in clinical studies assessing treatment efficacy in
CSDH. Given that there remains significant variability in man-
agement approaches to CSDH,4 it builds a strong case for the de-
velopment of a core outcome set that would homogenize the
outcome domains and definitions for future studies. Such a core
outcome set would promote the collection of robust outcome data in
individual studies, aiding cross-study comparisons and the devel-
opment of evidence-based treatment algorithms and guidelines for
this common neurosurgical condition.
The findings of the present study are not surprising. Such het-
erogeneity in the measurement of outcome reporting has been es-
tablished in a number of other specialties, including general
surgery,16–19 intensive care,20 and obstetrics.21 Specifically to
CSDH, difficulties in amalgamating data from individual studies
due to heterogeneous definitions and outcome measures have been
identified as limitations in all three large contemporary meta-
analyses of CSDH.2,4,7 However, the systematic evaluation and
quantification of this heterogeneity is a crucial stepping-stone to the
informed development of the core outcome set for CSDH.
Outcome domains
A number of the different outcome domains identified in this
study (Table 2), such as mortality and complications are crucial to
any disease process, and specifically to surgical conditions, where
thorough evaluation of morbidity and mortality is necessary to
evaluate both efficacy and safety. The consensus process will be
crucial in identifying a structured way of identifying and classify-
ing morbidity/complications (e.g., the Clavien-Dindo classifica-
tion),15 which are often under-reported in retrospective studies.
Historically, the most important outcome domain in CSDH has
been recurrence, as it is a relatively disease-specific outcome
measure. This is reflected in the number of studies that reported this
outcome (96; 94.1%) and the number of studies that set out to
specifically examine factors that influenced recurrence (22;
21.6%). However, as we identified during our recent systematic
review of minimally-invasive techniques for CSDH,22 the hetero-
geneity in definitions and time-points of recurrence precludes
amalgamation of data and undermines any attempt at meta-analysis.
Recurrence will no doubt remain a cornerstone of the evaluation
of treatment options for CSDH, but recent emphasis has shifted
towards a more holistic assessment provided by global functional
outcomemeasures such as the GOS andmRS.3,5 The GOSwas used
in 14.7% of the studies, whereas the mRS was used in 4.9%. These
global assessment tools are not specific to CSDH and were origi-
nally developed for evaluating functional outcomes in severe TBI
(GOS)23 and stroke (mRS).24 Another issue revolves around
FIG. 6. Functional outcomes and time-points used in the 41 studies that reported functional outcomes.
Table 2. Outcome Domains Identified
in the Present Study
Outcome domain
Number of studies including
outcome domain
Mortality 65 (63.7%)
Complications 49 (48.0%)
Recurrence 96 (94.1%)
Functional outcome 41 (40.2%)
Radiological outcome 39 (38.2%)
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analysis of these scales; historically, both have been reported as a
dichotomized outcome into ‘‘good’’ and ‘‘poor,’’ but recent evi-
dence suggests ordinal analysis increases statistical power and
should therefore be the preferred option.25
In addition to the holistic assessment of the patient, the detailed
assessment of surgical and peri-operative complications is crucial
in the decision-making process of whether or not to offer CSDH
patients surgical intervention. It was noteworthy that only 48.0% of
the studies reported complications and none of them used an es-
tablished classification system. In addition to surgical complica-
tions, it is also important to reinforce the importance of reporting
medical complications, especially in the elderly population, which
is more likely to suffer adverse effects from conditions like
hospital-acquired infections.
The utility of radiological outcomes as a domain remains con-
tentious, especially considering the radiation exposure, cost, and
limited utility associated with routine early post-operative CT scans.
Certainly, at our institution, routine post-operative scanning is not
undertaken and is based on clinical need and there is recent data to
suggest that it does not influence post-operative management.26
Study limitations
The limitations of the current study relate to the search criteria.
Selecting only English language full-text studies was driven by the
observation that definitions of outcomes are often omitted in
abstracts/short reports and would be difficult to elicit from non-
English language studies. In addition, the date limitation was set to
ensure a contemporary cohort of studies measuring relevant out-
comes. Despite these limitations, we feel we have successfully
satisfied the aims of the study in providing a strong basis for the
consensus process to occur.
Future directions
As stated in the introduction, this systematic review repre-
sents the first step in the process of developing a core outcome
set for CSDH. It has illustrated the heterogeneity of outcome
measures used in the current CSDH literature and has success-
fully built a case for the development of a consensus-based core
outcome set.
We aim to derive the core outcome set for CSDH via a combi-
nation of established methods for developing core outcome sets.14
First, we aim to conduct a structured Delphi survey of all relevant
stakeholders with clear pre-determined criteria for achieving a
majority opinion to determine the outcome domains and confirm/
refine this outcome set via a consensus conference.
In addition to the development of a core outcome set, the CODE-
CSDH project (Fig. 7) also aims to develop a set of common data
elements for CSDH. This would standardize the data elements to be
collected by future CSDH studies, ensuring homogenous and
consistent reporting of demographic data, pre-operative status, and
intra-operative details to further facilitate cross-study comparisons
and amalgamation of data across studies.
Conclusion
This systematic review highlights the heterogeneity of outcome
reporting in clinical efficacy studies of CSDH. It demonstrates the
FIG. 7. Aims and overview of the Core Outcomes and Common Data Elements in Chronic Subdural Hematoma (CODE-CSDH) project.
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lack of a robust evidence-based approach to the management of this
common neurosurgical condition and identifies the need for the
development of a robust, patient-centered set of core outcome
measures for CSDH as part of the CODE-CSDH project.
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